Last reviewed · How we verify
ABBV-075
At a glance
| Generic name | ABBV-075 |
|---|---|
| Also known as | Mivebresib |
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis (PHASE1)
- A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-075 CI brief — competitive landscape report
- ABBV-075 updates RSS · CI watch RSS
- AbbVie portfolio CI